Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review

Marlies De Bocka  Eva Hulstaertb  Vibeke Krusea  Lieve Brochezb

aDepartment of Medical Oncology, Ghent University Hospital, Ghent, Belgium;  
bDepartment of Dermatology, Ghent University Hospital, Ghent, Belgium

Keywords
Psoriasis · Checkpoint inhibitors · Anti-PD-1 · Anti-PDL-1 · Immune-related adverse events

Abstract
Objective: The incidence of immune-related adverse events is growing as the use of checkpoint inhibitors is exponentially increasing. Cutaneous adverse events are among the most frequent immune-related adverse events. The purpose of this case report and literature review is to highlight psoriasis as a potential adverse event with need for early recognition. Case Report and Literature Review: We describe the case of a 65-year-old woman with psoriasis exacerbation while treated with nivolumab (anti-PD-1) for a stage IV melanoma. She had a history of scalp psoriasis but she presented with psoriatic lesions on both lower and upper limbs. Our patient was treated with topical steroids. So far, 34 other cases with an exacerbation of psoriasis during treatment with anti-PDL-1 or PD-1 therapy have been reported in the literature. A broad range of therapies are described, without any available guidelines for this particular condition. Conclusion: Psoriasis exacerbation is an established side effect of PD-1/PDL-1 checkpoint inhibitors with 35 reported cases. Early recognition and management are
challenging as there are no clear guidelines available. A close collaboration between oncologist and dermatologist is mandatory to manage this immune-related adverse event.

© 2018 The Author(s) Published by S. Karger AG, Basel

Introduction

The use of immune checkpoint inhibitors (ICI) is exponentially increasing as it has become the standard of care for several cancer types. Currently, 2 types of ICI are used in the clinic: first, anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and second, anti-programmed cell death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitors. Inherent to the mechanism of action, immune-related adverse events (irAEs) are seen. Every organ is at risk, but skin toxicity is among the most frequent adverse events. Nonspecific maculopapular rash and pruritus represent the most common manifestations [1]. Other entities are less frequent and not so well documented. We present a case of psoriasis vulgaris exacerbation in a patient treated with nivolumab (anti-PD-1). The purpose of this paper is to point to the possibility of psoriasis vulgaris exacerbation as a potential irAE and to discuss the management of this adverse event.

Case Presentation

A 65-year-old woman presented with multiple itchy erythematous plaques on both lower and upper limbs ongoing for 1 week. In addition, psoriasiform scales on the scalp and retroauricular were observed. Full-body inspection revealed no other skin lesions. The patient was in good general condition. She had no other complaints and felt generally well. She denied systemic complaints such as weight loss, night sweats, fever, dyspnea, cough, or gastrointestinal symptoms. The patient had been treated with nivolumab 3 mg/m² (anti-PD-1) every 2 weeks for a stage IV melanoma. At the time of presentation, the treatment had been administered 11 times. Two years ago, she was diagnosed with a stage IV melanoma, positive for the BRAF V600 mutation. She was diagnosed with lymph node, subcutaneous, and brain metastases. Nivolumab was initiated as a third-line treatment, after a BRAF enzyme inhibitor and ipilimumab (CTLA-4 inhibitor). Iplimumab was stopped after 2 cycles because of grade 3 diarrhea. Since the treatment with nivolumab, a disease stabilization was observed. The patient had a known history of scalp psoriasis, type II diabetes, and hypertension. Her regular medication included lorametazepam, gliclazide, metoprolol, pantoprazole, and momethasone nasal spray.

Based on the clear clinical image, the patient was diagnosed with a psoriasis vulgaris exacerbation. The clinical image is shown in Figure 1. No skin biopsy was obtained. Local treatment with corticosteroids was initiated. Additionally, on patient request, the interval of nivolumab was extended from 2 weeks to 3 weeks, because she noticed a flare-up of the skin lesions after every nivolumab administration. Dosing at 3-week intervals, in combination with the local corticoid treatment, led to successful control of the psoriatic lesions. No systemic corticoids were administered. The patient had a stable disease for 14 months after the start of
nivolumab. Then, she developed progressive brain metastasis with an intracranial hemorrhage and died.

**Literature Review**

A bibliographic search was conducted on PubMed using the key words: “psoriasis” and “nivolumab,” “pembrolizumab,” “atezoluzimab,” “anti PD-1,” or “anti PDL-1.” Thirty-four cases with psoriasis linked to anti-PD-1 or anti-PDL-1 treatment were retained. An overview is given in Table 1 and Table 2. Twelve individual cases were described. Two authors published a collection of 17 and 5 cases, respectively, in 1 publication [2, 3]. Two additional publications also reported on psoriasis exacerbation but were not included in the tables because detailed information is missing [4, 5].

**Discussion**

We describe an exacerbation of a mild pre-existing psoriasis under anti-PD-1 therapy. An extension of the disease with new localizations was observed. We hypothesize that nivolumab was the trigger to the psoriasis exacerbation in our patient. However, we should mention that a psoriasis exacerbation can be triggered by multiple factors, such as stress and skin injury. In our case, the sequence of events and a clearly observed flare-up of the lesions after each anti-PD-1 infusion suggest a causal link between the administration of nivolumab and the psoriasis exacerbation. Indeed, several cases of psoriasis exacerbation following PD-1 or PDL-1 inhibition have been reported. In Table 1 and Table 2, we describe 34 other cases. The majority of cases show a psoriasis flare in patients with pre-existing disease, but a new-onset disease has been reported in 5 cases. Apart from these case reports, 2 publications on adverse events of anti-PD-1 mention psoriasis exacerbation. Danlos et al. [4] report a psoriasis flare in 4 out of 13 patients with psoriasis and Menzies et al. [5] report a flare in 3 out of 6 patients. The number of cases reported suggests that psoriasis exacerbation after ICI may be more common. However, reliable data on the prevalence and incidence of psoriasis in patients treated with anti-PD-1/PDL-1 antibodies are still lacking. In order to detect side effects at an early stage, it is recommended that these side effects of immunotherapy are searched for during each clinical examination. Registration in a systematic way is needed to obtain reliable epidemiologic data. This might also have a predictive value as some retrospective data suggested a better outcome for patients with cutaneous irAEs [6, 7]. At this moment it is unclear whether this is true for psoriasis induced by ICI.

A possible rationale for the pathogenesis can be given but remains speculative. Psoriasis is known as a T-cell- and dendritic-cell-mediated disease. IL-17 and IL-22 produced by T helper (Th) 1, 17, and 22 cells play an important role [8]. Th cells are downregulated by the PD-1 pathway. By inhibiting this pathway, an upregulation of Th-17 cells is observed [9]. Th-17 upregulation might be the explanation why this patient had psoriasis exacerbation parallel to the anti-PD-1 infusion.

The recognition of psoriasis induced by ICI is important for adequate management. General management for skin toxicity of ICI describes the use of topical emollients, antihistamines,
and corticoids [10]. For psoriasis, a more specific approach is needed. Prior recommendations for drug-induced psoriasis were to stop the causal drugs and start classic treatment options for psoriasis vulgaris. These treatment options are currently topical corticosteroids, vitamin D analogues, ultraviolet-based phototherapy, and systemic treatments, such as methotrexate, acitretin, and fumaric acid esters, and biologics [11]. Because of the underlying malignant condition, cyclosporine and many of the novel biologic agents are preferably avoided in patients with PD-1/PDL-1-induced psoriasis unless other severe irAEs are present, e.g., ICI-induced colitis not responding to systemic corticotherapy [3]. Our patient was successfully treated with topical steroids and prolongation of the dosing interval of nivolumab. Indeed, some cases describe good results with topical treatment with corticoids and vitamin D analogues [12–15]. However, in several cases local treatment was insufficient with need for oral prednisolone [2, 16, 17], acitretin (vitamin A derivate), or phototherapy [2, 16, 18, 19]. One patient with concomitant psoriasis arthritis was also treated with oral methotrexate [20]. In most cases, psoriatic lesions were controlled without the need to permanently discontinue the anti-PD-1/PDL-1 therapy; often, only a short break is reported. If psoriasis exacerbation or de novo psoriasis is suspected, we suggest a rapid referral to a dermatologist to initiate a proper local and if needed systemic treatment. With proper treatment, a discontinuation of the ICI can be avoided in most cases.

**Conclusion**

Psoriasis exacerbation is an established side effect of PD-1/PDL-1 checkpoint inhibitors with 35 reported cases. Early recognition and management are challenging with no clear guidelines available. A close collaboration between oncologist and dermatologist is mandatory to manage this specific irAE.

**Statement of Ethics**

Written informed consent was obtained from the patient.

**Disclosure Statement**

The authors have no conflicts of interest to disclose.

**Funding Sources**

There were no funding sources for this work.
References

1. Sibaud V, Meyer N, Lamant L, Vigariés E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016 Jul;28(4):254–63.

2. Bonigé J, Raynaud-Danzel C, Hureaux J, Kramkér N, Blom A, Jeudy G, et al.; Groupe de Recherche sur le Psoriasis and the Groupe Cancérologie Cutanée of the Société Française de Dermatologie the GEM Resopso, Apsoderm and the Groupe Français de Pneumo-Cancérologie. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol. 2017 May;31(5):e254–7.

3. Voudouri D, Nikolaou V, Laschos K, Charpidou A, Soupos N, Triantafyllopoulou I, et al. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer. 2017 Nov - Dec;41(6):407–12.

4. Danlos FX, Voisin AL, Deyerre V, Michot JM, Routier E, Taillade L, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018 Mar;91:21–9.

5. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong AN, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017 Feb;28(2):368–76.

6. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res. 2016 Feb;22(4):886–94.

7. Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol. 2018 Mar;4(3):374–8.

8. Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016 Jan;38(1):11–27.

9. Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T. Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma. Acta Derm Venereol. 2016 Feb;96(2):259–60.

10. Haenen JB, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al.; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul;28 suppl 4;iv119–42.

11. Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl). 2017 Dec;7:87–94.

12. Murata S, Kaneko S, Harada Y, Aoi N, Morita E. Case of de novo psoriasis possibly triggered by nivolumab. J Dermatol. 2017 Jan;44(1):99–100.

13. Ruiz-Bañobre J, Abdulkader I, Anido U, León L, López R, García-González J. Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. APMIS. 2017 Mar;125(3):259–63.

14. Yamamoto T. Anti-Programmed Cell Death-1 Induced Plaque and Guttate Psoriasis. Indian J Dermatol. 2018 Jan-Feb;63(1):88–9.

15. Totenchy MB, Ezaldein HH, Ko CJ, Choi JN. Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma. JAMA. 2016 May;152(5):590–2.

16. Kato Y, Otsuka A, Miyachi Y, Kabashima K. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):e89–91.

17. Ohtsuka M, Murata T, Mori T, Ishihama M, Yamamoto T. Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma. J Dermatol. 2015 Jul;151(7):797–9.

18. Phadke SD, Ghabour R, Swick BL, Swenson A, Milhem M, Zakharia Y. Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient Cases. J Investig Med High Impact Case Rep. 2016 Oct;4(4):2324709616674316.

19. Sahuquillo-Torralba A, Ballestre-Sánchez R, Pujol-Marco C, Botella-Estrada R. Pembrolizumab: a new Drug That Can Induce Exacerbations of Psoriasis. [English Edition]. Actas Dermosifiliogr. 2016 Apr;107(3):264–6.

20. Law-Ping-Man S, Martin A, Briens E, Tissier L, Safa G. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology (Oxford). 2016 Nov;55(11):2087–9.

21. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol. 2015 Nov;151(11):1206–12.
Fig. 1. Psoriatic lesions on both lower and upper limbs.
**Table 1. Overview of psoriasis exacerbations and de novo psoriasis in patients treated with anti-PD-1/anti-PDL-1 therapy**

| Patient age, years/ gender | Cancer type | Treatment regimen | Time between start of PD-1/PDL-1 inhibitor and appearance of psoriasis | Personal history of psoriasis | Psoriasis management | Discontinuation of PD-1/PDL-1 inhibitor | Tumor response to PD-1/PDL-1 inhibitor | First author [Ref.], year |
|---------------------------|-------------|-------------------|-------------------------------------------------|-----------------------------|---------------------|------------------------|----------------------------------------|---------------------------|
| 80/M                      | Primary oral mucosal melanoma | Nivolumab 2 mg/kg every 3 weeks | 12 weeks | No | Oral prednisolone, resulted in therapeutic effect | No | 3 months after the last dose of nivolumab, the lesions on the palate decreased in size; no melanoma cells were found in a biopsy taken from the upper lip | Ohtsuka [17], 2015 |
| 65/M                      | Metastatic oral mucosal melanoma | Nivolumab 2 mg/kg every 3 weeks, after subcutaneous interferon-β injections for 5 days | 3 weeks | Yes | – Topical steroid (clobetasol propionate 0.05%) and vitamin D3 analogue, without response – UVB therapy, without response – Oral etretinate 30 mg/day, resulted in therapeutic effect | No | NA | Kato [16], 2015 |
| 45/M                      | Metastatic renal cell carcinoma | Nivolumab 3 mg/kg every 2 weeks | 2 weeks | No | Calcipotriol/betamethasone gel, resulted in therapeutic effect | Yes; interruption of 21 days | Partial response on CT scan | Ruiz-Bañobre [13], 2017 |
| 87/M                      | Metastatic cutaneous melanoma | Nivolumab 2 mg/kg every 3 weeks | 6 weeks | Yes | Systemic corticoids (0.5 mg/kg), resulted in therapeutic effect | Yes; interruption because of concomitant pneumonitis | NA | Matsumura [9], 2015 |
| 80/F                      | Metastatic cutaneous melanoma | Pembrolizumab Between 3 and 6 weeks | NA | Local corticoids | Yes | Yes | Totonchy [15], 2016 |
| 67/M                      | Metastatic adenocarcinoma of the lung | Pembrolizumab | 3 weeks | Yes | Acitretin | Yes; interruption of 4 weeks | NA | Sahuquillo-Torrailha [19], 2016 |
| NA                        | NA | Pembrolizumab | 9 weeks | Yes | Topical and systemic corticoids | Yes; interruption of 1 week | NA | Sanlorenzo [21], 2015 |

NA, not applicable.
### Table 2. Overview of psoriasis exacerbations and de novo psoriasis in patients treated with anti-PD-1/anti-PDL-1 therapy (continued)

| Patient age, years/gender | Cancer type | Treatment regimen | Time between start of PD-1/PDL-1 inhibitor and appearance of psoriasis | Personal history of psoriasis | Psoriasis management | Discontinuation of PD-1/PDL-1 inhibitor | Tumor response to PD-1/PDL-1 inhibitor | First author [Ref.], year |
|---------------------------|-------------|-------------------|---------------------------------------------------------------------|-------------------------------|---------------------|----------------------------------------|---------------------------------------|-------------------------------|
| 17 patients: age 35-87 years/F/M | Melanoma/ lung carcinoma | Pembrolizumab/ nivolumab | NA | NA | Topical, systemic corticosteroids, acitretin, phototherapy | NA | NA | Bonigen [2], 2017 |
| 67/M | Advanced non-small cell lung cancer | Nivolumab 3 mg/kg every 3 weeks | 3 weeks | No | Topical corticoids, resulted in therapeutic effect | No | NA | Yamamoto [14], 2018 |
| 67/M | Stage IV melanoma | Pembrolizumab 2 mg/kg every 3 weeks | 15 weeks | Yes | Acitretin and narrow band ultraviolet B phototherapy | Yes; interruption of 4 weeks | Yes | Phadke [18], 2016 |
| 5 patients: mean age 66 years/F/M | 3 NSCLC, 1 papillary urothelial carcinoma, 1 squamous cell carcinoma of the tonsil | 3 patients treated with anti-PD-1 therapy (1 with pembrolizumab, 2 with nivolumab) 2 patients treated with anti-PDL-1 therapy (durvalumab) | Between 2 weeks and 2 months | In 3 out of 5 patients the personal history was positive for psoriasis | Topical steroids, ultraviolet B phototherapy, systemic steroids | In 1 out of 5 patients therapy was interrupted | NA | Voudouri [3], 2017 |
| 89/M | Metastatic melanoma | Nivolumab 3 mg/kg every 2 weeks | 2 weeks | No | Calcipotriol/ betamethasone dipropionate (local) | No | No | Murata [12], 2017 |
| 80/M | NSCLC | Nivolumab 3 mg/kg every 2 weeks | 16 weeks | No | Oral methotrexate at a dose of 10 mg/week in combination with low-dose 15 mg oral prednisone/ day and topical corticosteroids | Yes; interruption of 4 weeks | Yes | Law-Pingman [20], 2016 |
| 65/F | Metastatic melanoma | Nivolumab 3 mg/kg every 2 weeks | 20 weeks | Yes | Topical corticosteroids, prolongation of treatment interval to 3 weeks | Yes; nivolumab every 3 weeks instead of every 2 weeks | Yes | Our case |

NA, not applicable.